# 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

> **NCT00225537** · PHASE2 · UNKNOWN · sponsor: **MTmedical Institute of Health** · enrollment: 160 (—)

## Conditions studied

- Chronic Hepatitis C
- Chronic Hepatitis B

## Interventions

- **DRUG:** 4-Methylumbelliferone (Heparvit®)

## Key facts

- **NCT ID:** NCT00225537
- **Lead sponsor:** MTmedical Institute of Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 160 (—)
- **Last updated:** 2006-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225537, "4-Methylumbelliferone as a Treatment for Chronic HBV/HCV". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00225537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*